0.1908

2.30% -0.0045

X 4 Pharmaceuticals Inc (XFOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

X 4 Pharmaceuticals Inc stock is traded at $0.1908, with a volume of 899.05K. It is down -2.30% in the last 24 hours and down -39.18% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Previous Close:

$0.1953

Open:

$0.1981

24h Volume:

899.05K

Relative Volume:

0.29

Market Cap:

$35.57M

Revenue:

Net Income/Loss:

$-16.76M

P/E Ratio:

-2.385

EPS:

-0.08

Net Cash Flow:

$-132.97M

1W Performance:

-9.83%

1M Performance:

-39.18%

6M Performance:

-61.59%

1Y Performance:

-84.03%

1-Day Range:

$0.1893

$0.205

1-Week Range:

$0.1893

$0.2275

52-Week Range:

$0.1876

$1.39

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name

X 4 Pharmaceuticals Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

857-529-8300

Address

61 NORTH BEACON STREET, BOSTON, MA

Employee

143

Twitter

@x4pharma

Next Earnings Date

2025-03-25

Latest SEC Filings

XFOR's Discussions on Twitter

Compare XFOR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XFOR X 4 Pharmaceuticals Inc	0.1908	35.57M	0	-16.76M	-132.97M	-0.08
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral
Aug-30-23	Resumed	B. Riley Securities	Buy
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight
Dec-12-22	Initiated	Piper Sandler	Overweight
Dec-23-19	Initiated	Oppenheimer	Outperform
Dec-18-19	Initiated	ROTH Capital	Buy
Dec-09-19	Upgrade	Citigroup	Neutral → Buy
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy
Jun-05-19	Initiated	Cowen	Outperform

View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

Apr 17, 2025

Top 10 pharma companies in India by market cap [2025] - Forbes India

Apr 17, 2025

Analyzing X4 Pharmaceuticals (NASDAQ:XFOR) & Pluri (NASDAQ:PLUR) - Defense World

Apr 17, 2025

Apr 16, 2025

Ionis to hold first quarter 2025 financial results webcast - Quantisnow

Apr 16, 2025

Apr 15, 2025

Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace

Apr 15, 2025

Apr 14, 2025

Director Foehr Matthew W exercised 20,786 shares at a strike of $8.00, increasing direct ownership by 19% to 132,036 units (SEC Form 4) - Quantisnow

Apr 14, 2025

Apr 13, 2025

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com

Apr 13, 2025

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - marketscreener.com

Apr 13, 2025

Apr 11, 2025

SEC Form DEF 14A filed by Sensei Biotherapeutics Inc. - Quantisnow

Apr 11, 2025

Apr 10, 2025

X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison Lawton - MarketScreener

Apr 10, 2025

Fierce Biotech Layoff Tracker 2025: Pfizer sells site, cuts staff; Opthea reduces workforce by 65% - Fierce Biotech

Apr 10, 2025

Apr 09, 2025

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy - BioSpace

Apr 09, 2025

Apr 04, 2025

Now Pharma Inc looks for cure as Trump delivers dose of anxiety - The Economic Times

Apr 04, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 04, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Apr 04, 2025

Apr 03, 2025

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - Quantisnow

Apr 03, 2025

Apr 01, 2025

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 01, 2025

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 01, 2025

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia - BioSpace

Apr 01, 2025

Mar 31, 2025

Ionis to present at upcoming investor conferences - Quantisnow

Mar 31, 2025

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 31, 2025

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript - MSN

Mar 31, 2025

Mar 29, 2025

Research Analysts Issue Forecasts for XFOR FY2028 Earnings - Defense World

Mar 29, 2025

Mar 28, 2025

X4 Pharmaceuticals (NASDAQ:XFOR) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 28, 2025

Mar 27, 2025